TNGX Stock Catalyst: Tango Therapeutics Announced Initial Data from Phase 1/2 Study

Jun 8, 2026 · 7:01am ET

Company reported a 92% Objective Response Rate in the study.

Max move

+94.5%

High of day $40.44

Sparker timei

7:01am ET

TNGX · Jun 8, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Tango Therapeutics announced Tango Therapeutics announced initial data from an ongoing Phase 1/2 study of Vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in patients with MTAP-Deleted and RAS-Mutant Metastatic PDAC.

The announcement cited 92% Objective Response Rate.

Tango Therapeutics, Inc. has a free float of 76,565,411 shares and 144,647,982 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time TNGX sparks.

Download Sniper App →

Catch the next TNGX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →